← FDA DRUG APPROVALS

FDA ANDA · ANDA217430

LEVOCARNITINE

Sponsor: DEVA HOLDING AS

APPLICATION
ANDA217430
TYPE
ANDA
ORIGINAL APPROVAL
2025-06-30
LATEST ACTION
2025-06-30
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

LEVOCARNITINEPrescription
LEVOCARNITINE 200MG/ML · INJECTABLE · INJECTION

Approval history

2025-06-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →